| 1 |
32647892 | Interleukin-7 and interleukin-15 drive CD4+CD28null T lymphocyte expansion and function in patients with acute coronary syndrome. | 2021 Jul 7 |
2 |
| 2 |
32738245 | Granzyme B Inhibition by Tofacitinib Blocks the Pathology Induced by CD8 T Cells in Cutaneous Leishmaniasis. | 2021 Mar |
1 |
| 3 |
33317858 | Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib. | 2021 May |
1 |
| 4 |
34757416 | Treatment of Persistent Erythema Multiforme With Janus Kinase Inhibition and the Role of Interferon Gamma and Interleukin 15 in Its Pathogenesis. | 2021 Dec 1 |
2 |
| 5 |
31375130 | Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. | 2019 Aug 2 |
1 |
| 6 |
25738293 | T cell-activated signaling pathways and locally produced cytokines as potential targets in celiac disease. | 2015 |
1 |
| 7 |
23904478 | Insulin-dependent diabetes induced by pancreatic beta cell expression of IL-15 and IL-15Rα. | 2013 Aug 13 |
1 |
| 8 |
22607938 | Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease. | 2012 Jul |
1 |
| 9 |
22960764 | Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. | 2012 Sep 15 |
2 |
| 10 |
21106989 | CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. | 2011 Feb 10 |
1 |